Mercaptopurine is a purine antimetabolite that interferes with nucleic acid synthesis, inhibiting the growth of rapidly dividing cells, especially lymphoblasts.
Recommended for:
Acute lymphoblastic leukaemia (induction and maintenance)
Chronic myeloid leukaemia
Inflammatory bowel disease (Crohn’s, ulcerative colitis)
Immunosuppression post-transplant (only as prescribed)
Used in the treatment of acute and chronic forms of leukaemia, particularly ALL and CML. May also be indicated for autoimmune bowel conditions as per physician's judgement.
The medicine is taken orally at the same time each day, preferably after meals. Dosage is adjusted individually based on patient condition, body weight, and therapeutic protocol. Blood count monitoring is essential during treatment.
Contraindicated in patients with hypersensitivity to mercaptopurine, in pregnancy, or with severe liver impairment. Common side effects include bone marrow suppression, anaemia, liver toxicity, fatigue, immunosuppression, and gastrointestinal discomfort.
